Showing 401-410 of 1610 results for "".
ICSC: A History and Preview
https://modernod.com/topics/contact-lenses/icsc-a-history-and-preview/37913/Optometric Cornea, Cataract and Refractive Society
https://modernod.com/mod-issues/2021-oct/optometric-cornea-cataract-and-refractive-society/38306/A forum for clinicians, researchers, and business owners to connect over all things refractive.Coping in a Time of Crisis
https://modernod.com/topics/glaucoma/coping-in-a-time-of-crisis/38065/The Importance of Our Profession
https://modernod.com/topics/business/the-importance-of-our-profession/38214/What Does the Future of Optometry Look Like?
https://modernod.com/topics/glaucoma/what-does-the-future-of-optometry-look-like/38739/Eye on the Target: Navigating Ocular Challenges With ADC Cancer Therapies
https://modernod.com/cme/ophthalmology/eye-on-the-target-2421/33187/Specialists in eye care and oncology come together to discuss strategies to manage ocular toxicities associated with specific cancer drugs.Let’s Talk Cosmetometry
https://modernod.com/topics/ocular-surface/lets-talk-cosmetometry/38797/Intrepid Eye Society
https://modernod.com/mod-issues/2021-july-aug/intrepid-eye-society/38256/Working to empower the next generation.Glaukos' MIGS Technology Certified in Europe; New Phase 3 Data for Presbyopia Drop
https://modernod.com/podcasts/eyewire-news-the-podcast/glaukos-migs-technology-certified-in-europe-new-phase-3-data-for-presbyopia-drop/37091/Glaukos receives European Union certification for several of its MIGS technologies; Opus Genetics and Viatris present phase 3 results for their investigational presbyopia eye drop; and J&J launches the first and only daily disposable contact lens for people with both astigmatism and presbyopia.TFOS DEWS III Published
https://modernod.com/podcasts/eyewire-news-the-podcast/tfos-dews-iii-published/37089/The Tear Film and Ocular Surface Society publishes the third installment of the TFOS DEWS report; J&J launches the Tecnis Odyssey presbyopia-correcting IOL in Europe, the Middle East, and Canada; and Harrow acquires the exclusive US commercial rights to postoperative inflammation and pain drug B